Inclusion Criteria:

        Patients with relapsed and refractory high-grade pineoblastome (=rPB) and all of the
        following criteria will be considered for admission to the clinical trial:

          -  Children, adolescents and young adults 0 months to 25 years

          -  Signed written informed consent (patient or his/her parents/legal guardian)

          -  Females of childbearing age must have a negative urine pregnancy test prior to
             starting the study drug. The first pregnancy test must be performed within 10-14 days
             prior to the start of the study drug and the second pregnancy test must be performed
             within 24 hours prior to the start of study drug. The subject may not receive the
             study drug until the investigator has verified that the results of these pregnancy
             tests are negative.

          -  Females of childbearing age must comply with the institutional standards of birth
             control with a pearl index <1%. Contraception must be started at least four weeks
             before the start of the investigational therapy.

          -  Females of childbearing age must be willing to abstain from breastfeeding for the
             duration of the clinical trial and for at least 30 days after discontinuation of the
             clinical trial.

          -  Males must agree not to father a child and must use latex condom during any sexual
             contact with women of childbearing age during and for 6 months after therapy ends or
             is stopped, even if they have undergone successful vasectomy.

          -  Willing and able to complete the clinical trial procedures, as described in the
             protocol

          -  Non-smoker for at least the previous 3 months. Smoking is not allowed during the
             entire study period

          -  Abstain from alcohol within the last 24 hours before screening and before admission to
             the clinical trial center as well as during the entire clinical trial. The regular
             daily ethanol intake has to be less than 20g/day for at least the previous three
             months.

          -  Patients are required to have an absolute neutrophil count (ANC) ≥500/µL, hemoglobin
             ≥8g/dL (transfusion permitted), and an unsupported platelet count ≥30,000/µL unless:

               -  patient is refractory or relapsed early after primary therapy

        Exclusion Criteria:

        Patients presenting with any of the following criteria will not be included in this
        clinical trial:

          -  Pregnancy, nursing

          -  Patients who suffered from a thrombotic event and need anticoagulation (i.e. coumadine
             derivatives or low molecular weight heparin derivatives, LMWH)

          -  Patients with cardiac arrhythmias especially prolonged QT

          -  Patients with chronic inflammatory bowel diseases and/or bowel obstruction

          -  Patients with bilirubin serum levels 1,5 fold above the upper normal limit

          -  Vaccination with a live virus vaccine during the clinical trial

          -  Impaired liver function and/or impaired renal function (hepatic and renal index
             parameter two times above normal range; see below)

          -  Potentially unreliable subjects, probably non compliant subjects and those judged by
             the investigator to be unsuitable for the study

          -  Doubts about the patient's cooperation

          -  Any contraindications or known hypersensitivity to the IMPs or to any of the other
             components: (see SPC "Fachinformation")

          -  Known allergic reactions to the treatment medication

          -  Patients who were treated with radiation and/or chemotherapy for any other oncological
             condition

          -  Participation in any other interventional phase I to III trial

          -  Sexually active patients who refuse to use contraception according to the
             institutional requirements

          -  Patients with extremely poor general condition (Karnofsky or Lansky score <50%)

          -  Neutrophil count (ANC) <500/µL, hemoglobin <8g/dL (transfusion permitted), and an
             unsupported platelet count <30 000/µL

          -  12-lead ECG with QTc>500 msec / QTc>60 msec baseline

               -  Patients with hepatitis B reactivation